文献速递浆细胞疾病

JAM-A作为多发性骨髓瘤的预后因素和新治疗靶点

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.
PubMed 文献 · Leukemia · 2017-09-28

本研究探讨连接黏附分子-A(JAM-A)在多发性骨髓瘤(MM)中作为新靶点和临床生物标志物的潜力。研究评估了MM细胞系及147例不同疾病阶段MM患者骨髓穿刺和活检中的JAM-A表达,发现患者来源浆细胞中JAM-A水平升高与不良预后相关,且循环可溶性JAM-A(sJAM-A)水平在MM患者中较对照组显著升高。体外抑制JAM-A可损害MM迁移、集落形成、趋化、增殖和活力;体内使用抗JAM-A单克隆抗体(αJAM-A moAb)治疗可 impair 小鼠异种移植MM模型中的肿瘤进展。

要点

  • 患者来源浆细胞中JAM-A水平升高与MM不良预后相关。
  • MM患者循环sJAM-A水平较对照组显著升高。
  • 体外抑制JAM-A可损害MM迁移、集落形成、趋化、增殖和活力。

核心结论

  • 治疗靶向JAM-A具有预防MM进展的潜力,作者提出JAM-A可作为MM的生物标志物,sJAM-A可作为基于血清的临床分层标志物。

研究设计与样本

  • 研究评估了MM细胞系及147例不同疾病阶段MM患者骨髓穿刺和活检中的JAM-A表达。
  • 体内使用小鼠异种移植MM模型进行抗JAM-A单克隆抗体治疗实验。

主要发现

  • 患者来源浆细胞中JAM-A水平升高与不良预后相关。
  • MM患者循环sJAM-A水平较对照组显著升高。
  • 体外抑制JAM-A可损害MM迁移、集落形成、趋化、增殖和活力。
  • 体内抗JAM-A单克隆抗体治疗可 impair 小鼠异种移植MM模型中的肿瘤进展。

临床怎么用

  • 作者提出JAM-A可作为MM的生物标志物,sJAM-A可作为基于血清的临床分层标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cell adhesion in the multiple myeloma (MM) microenvironment has been recognized as a major mechanism of MM cell survival and the development of drug resistance. Here we addressed the hypothesis that the protein junctional adhesion molecule-A (JAM-A) may represent a novel target and a clinical biomarker in MM. We evaluated JAM-A expression in MM cell lines and in 147 MM patient bone marrow aspirates and biopsies at different disease stages. Elevated JAM-A levels in patient-derived plasma cells were correlated with poor prognosis. Moreover, circulating soluble JAM-A (sJAM-A) levels were significantly increased in MM patients as compared with controls. Notably, in vitro JAM-A inhibition impaired MM migration, colony formation, chemotaxis, proliferation and viability. In vivo treatment with an anti-JAM-A monoclonal antibody (αJAM-A moAb) impaired tumor progression in a murine xenograft MM model. These results demonstrate that therapeutic targeting of JAM-A has the potential to prevent MM progression, and lead us to propose JAM-A as a biomarker in MM, and sJAM-A as a serum-based marker for clinical stratification.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Solimando AG, Brandl A, Mattenheimer K, et al. JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia. 2017. PMID: 29064484. doi:10.1038/leu.2017.287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。